Modern Pharmacological Approach to the Treatment of Hodgkin Lymphoma
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.contributor.author | Ohfuji, Arisa | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Megyeri, Attila | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | |
| dc.date.accessioned | 2023-08-21T06:50:04Z | |
| dc.date.available | 2023-08-21T06:50:04Z | |
| dc.date.created | 2022-05-20 | |
| dc.description.abstract | The initial treatment for patients with Hodgkin lymphoma is based on the histologic characteristics of the disease, the stage at presentation, and the presence or absence of prognostic factors associated with poor outcome. Patients with early-stage Hodgkin lymphoma commonly receive combined-modality therapies that include abbreviated courses of chemotherapy followed by involved-field radiation treatment. In contrast, patients with advanced-stage Hodgkin lymphoma commonly receive a more prolonged course of combination chemotherapy, with radiation therapy used only in selected cases. For patients with relapse or refractory disease, salvage chemotherapy followed by high-dose treatment and an autologous stem cell transplant is the standard of care. For patients who are ineligible for this therapy or those in whom high-dose therapy and autologous stem cell transplant have failed, treatment with brentuximab vedotin is a standard approach. | |
| dc.description.corrector | LB | |
| dc.description.course | általános orvos | |
| dc.description.courselang | angol | |
| dc.description.degree | egységes, osztatlan | |
| dc.format.extent | 50 | |
| dc.identifier.uri | https://hdl.handle.net/2437/358275 | |
| dc.language.iso | en | |
| dc.rights.access | Hozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében. | |
| dc.subject | Hodgkin lymphoma | |
| dc.subject | chemotherapy | |
| dc.subject | brentuximab vedotin | |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | |
| dc.title | Modern Pharmacological Approach to the Treatment of Hodgkin Lymphoma |